EMBIOSYS INC.
DEVELOPMENT OF A WEARABLE, NON-INVASIVE, TREATMENT DEVICE FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC)
DEVELOPMENT OF A WEARABLE, NON-INVASIVE, TREATMENT DEVICE FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC) is a funding opportunity from EMBIOSYS INC., up to 188875, closing August 31, 2026.
Aug 31, 2026
(31d left)Overview
PROJECT SUMMARY/ABSTRACT Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is highly invasive, has limited treatment options, and is prone to recurrence and metastasis. The standard of care for TNBC patients involves neoadjuvant chemotherapy, followed by surgery and radiotherapy. Even with recent…